Table 2 Screening characteristics and outcomes of women with diabetes mellitus who underwent cervical screening via hr-HPV DNA testing and VIA (n = 198)
Screening characteristic | Estimate |
|---|---|
Normal vulval inspection findings, n (%) | 198 (100.0) |
Normal vaginal inspection findings, n (%) | 198 (100.0) |
Cervical inspection, n (%) | Â |
Normal | 195 (98.5) |
Abnormal | 3 (1.5) |
TZ type on visual inspectionα (VIA or colposcopy) |  |
1 | 4 (2.0) |
2 | 5 (2.5) |
3 | 185 (93.4) |
Missing, n = 4 |  |
Screening outcome (prevalence estimates) | Â |
Overall hr-HPV positive, % (95% CI) | 21.7 (16.1–28.1) |
HPV16 | 1.5 (0.3–4.4) |
HPV18 | 1.5 (0.3–4.4) |
Other HPV type(s) | 20.7 (15.3–27.0) |
hr-HPV-positive by DM type, % (95% CI) | Â |
Type 1 DM | 37.5 (15.2–64.6) |
Type 2 DM | 19.8 (13.9–26.7) |
Other/unspecified | 25.0 (8.7–49.1) |
Single vs. mixed hr-HPV infections, % (95% CI) | Â |
HPV16 only | 0.5 (0.0–2.8) |
HPV18 only | 0.5 (0.0–2.8) |
Other HPV type(s) only | 18.7 (13.5–24.8) |
HPV16 + other HPV type(s) | 1.0 (0.1–3.6) |
HPV18 + other HPV type(s) | 1.0 (0.1–3.6) |
VIA ‘positive’, % (95% CI) | 1.5 (0.3–4.4) |